Pulmonarydrug info
Pulmonary Hypertension tadalafil 20 MG Oral Tablet
What it is used for
ALYQ ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II - III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
1.1 Pulmonary
Arterial Hypertension ALYQ ® (tadalafil tablets, USP) is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II - III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective April 1, 2023. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
ALYQ ® (tadalafil, USP), an oral treatment for pulmonary arterial hypertension, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Tadalafil, USP has the molecular formula C 22 H 19 N 3 O 4 representing a molecular weight of 389.40.
The structural formula is: The chemical designation is pyrazino[1´,2´:1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-. It is a white or almost white powder that is practically insoluble in water, slightly soluble in methylene chloride, and freely soluble in dimethylsulfoxide. ALYQ ® (tadalafil tablets, USP) is available as white to off-white, oval shaped, film-coated tablets for oral administration. Each tablet contains 20 mg of tadalafil, USP and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, pregelatinized (corn) starch, sodium lauryl sulfate, titanium dioxide, and triacetin. structural formula
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective April 1, 2023. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance